BioTissue Reports Promising Phase 2 Trial Results for New Dry Eye Treatment
New York, Friday, 9 October 2026.
BioTissue announced positive Phase 2 clinical results for a novel dry eye therapy derived from human birth tissue, demonstrating significant symptom relief and safety without serious adverse events.
Clinical Trial Design and Safety Profile
The prospective, randomized, controlled, double-masked, multicenter Phase 2 study randomized 74 patients in a 1:1:1:1 ratio to receive one of three TTAX03 concentrations or a saline control [1]. Administration occurred under a bandage contact lens for 5 days, with safety evaluations conducted through 12 weeks [1]. Clinical findings indicate no treatment-related serious adverse events were recorded during the study period [1]. Patients receiving the highest dose experienced the greatest improvements in dry eye symptoms and corneal staining [1].
Regulatory Landscape and Competitive Trials
As of October 6, 2026, no cell, exosome, or Wharton’s jelly product is FDA-approved for the treatment of dry eye disease [2]. Current approved management strategies remain limited to artificial tears, prescription anti-inflammatory eye drops, and in-office procedures [2]. Competitor activity includes Okyo Pharma, which announced positive safety data for its ongoing OK-101 Phase 2 clinical trial [3]. Additionally, the VSJ-110 Phase 2 study completed enrollment with 160 participants [4]. This enrollment figure exceeds the BioTissue study size by 86 participants, indicating varying scales of investigation within the sector [1][4].
Technological Foundation and Future Development
BioTissue utilizes proprietary CryoTek® technology for cryopreserved amniotic membrane products to maintain structural and functional integrity [1]. Company products have been used in over 1 million human implants and are supported by 420 peer-reviewed publications [1]. The company intends to conduct additional research to further evaluate efficacy and establish appropriate dosing and treatment regimens for TTAX03 [1]. BioTissue is currently pursuing Biologic License Applications and conducting multiple Investigational New Drug clinical trials to address unmet clinical needs in ophthalmology [1].